<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1729">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04354584</url>
  </required_header>
  <id_info>
    <org_study_id>COV2ICU-DK</org_study_id>
    <secondary_id>H-20023159</secondary_id>
    <secondary_id>R349-2020-540</secondary_id>
    <nct_id>NCT04354584</nct_id>
  </id_info>
  <brief_title>Compartmental Inflammation in Mechanically Ventilated Patients With COVID-19</brief_title>
  <acronym>COV2ICU-DK</acronym>
  <official_title>Early and Late Pulmonary and Systemic Inflammation in Critically Ill, Mechanically Ventilated Patients With Verified COVID-19</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hvidovre University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hvidovre University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the present study is to examine the inflammatory response in the pulmonary
      compartment and blood of critically ill patients admitted to the ICU with COVID-19.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The mechanisms of the ARDS-like respiratory failure observed in patients with COVID-19 are
      currently unknown, but may be related to a distinct local immune response within the lung. In
      the present study, we will examine the cellular and humoral pulmonary immune response in
      mechanically ventilated patients admitted to the ICU with COVID-19 by examining immune cell
      profiles, cytokine patterns, and the complement pathway in bronchoalveolar lavage fluid, and
      relate it to the concomitant systemic inflammatory response. We will examine the patients on
      day 1-3 and 7-9 after ICU admission.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 6, 2020</start_date>
  <completion_date type="Anticipated">April 6, 2021</completion_date>
  <primary_completion_date type="Anticipated">April 6, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>White blood cell counts</measure>
    <time_frame>Day 0 (subsequent to study inclusion in the ICU)</time_frame>
    <description>Total white blood cells, neutrocytes, lymphocytes, and monocytes in bronchoalveolar lavage fluid and blood</description>
  </primary_outcome>
  <primary_outcome>
    <measure>White blood cell counts</measure>
    <time_frame>Day 7</time_frame>
    <description>Total white blood cells, neutrocytes, lymphocytes, and monocytes in bronchoalveolar lavage fluid and blood</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Lymphocyte populations</measure>
    <time_frame>Day 0 (subsequent to study inclusion in the ICU)</time_frame>
    <description>Cell populations and subpopulations evaluated by 10 colored flow cytometry (B cells, T cells, TCR subsets, Tregs/Th17, dendritic cells, myeloid cells and neutrophils) in bronchoalveolar lavage fluid and blood</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Lymphocyte populations</measure>
    <time_frame>Day 7</time_frame>
    <description>Cell populations and subpopulations evaluated by 10 colored flow cytometry (B cells, T cells, TCR subsets, Tregs/Th17, dendritic cells, myeloid cells and neutrophils) in bronchoalveolar lavage fluid and blood</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cytokines</measure>
    <time_frame>Day 0 (subsequent to study inclusion in the ICU)</time_frame>
    <description>Multiplex assay for measuring cytokines in bronchoalveolar lavage fluid and plasma (e.g. IL-1-beta, IL-1RA, IL-2, IL-6, IL-8, IL-10, IL-17, IL-18, IL-33, IL-35, TGF-beta, TNF-alpha, HMGB1)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cytokines</measure>
    <time_frame>Day 7</time_frame>
    <description>Multiplex assay for measuring cytokines in bronchoalveolar lavage fluid and plasma (e.g. IL-1-beta, IL-1RA, IL-2, IL-6, IL-8, IL-10, IL-17, IL-18, IL-33, IL-35, TGF-beta, TNF-alpha, HMGB1)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lectin complement pathway</measure>
    <time_frame>Day 0 (subsequent to study inclusion in the ICU)</time_frame>
    <description>MBL, ficolin-1, ficolin-2, ficolin-3, and MASPs in bronchoalveolar lavage fluid and plasma</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lectin complement pathway</measure>
    <time_frame>Day 7</time_frame>
    <description>MBL, ficolin-1, ficolin-2, ficolin-3, and MASPs in bronchoalveolar lavage fluid and plasma</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Microorganisms</measure>
    <time_frame>Up to 12 weeks</time_frame>
    <description>Growth of pathogenic microorganisms in body fluids (e.g. urine, blood, bronchoalveolar lavage fluid)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Respiratory pathogens</measure>
    <time_frame>Day 0 (subsequent to study inclusion in the ICU)</time_frame>
    <description>Respiratory filmarray PCR for testing for pathogens</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Respiratory pathogens</measure>
    <time_frame>Day 7</time_frame>
    <description>Respiratory filmarray PCR for testing for pathogens</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ribosomal RNA in the airways</measure>
    <time_frame>Day 0 (subsequent to study inclusion in the ICU)</time_frame>
    <description>16S ribosomal RNA (rRNA) and 18S rRNA PCR for bacterial or fungal pathogen identification in bronchoalveolar lavage fluid</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ribosomal RNA in the airways</measure>
    <time_frame>Day 7</time_frame>
    <description>16S ribosomal RNA (rRNA) and 18S rRNA PCR for bacterial or fungal pathogen identification in bronchoalveolar lavage fluid</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Levels of SARS-CoV-2 in the airways</measure>
    <time_frame>Day 0 (subsequent to study inclusion in the ICU)</time_frame>
    <description>Semiquant PCR of SARS-CoV-2 in bronchoalveolar lavage fluid</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Levels of SARS-CoV-2 in the airways</measure>
    <time_frame>Day 7</time_frame>
    <description>Semiquant PCR of SARS-CoV-2 in bronchoalveolar lavage fluid</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Mortality</measure>
    <time_frame>Up to 6 months</time_frame>
    <description>ICU mortality</description>
  </other_outcome>
  <other_outcome>
    <measure>Mortality II</measure>
    <time_frame>Up to 6 months</time_frame>
    <description>In hospital mortality</description>
  </other_outcome>
  <other_outcome>
    <measure>Blood markers of inflammation</measure>
    <time_frame>Daily assessment in the ICU up to 12 weeks</time_frame>
    <description>C-reactive protein, procalcitonin, ferritin</description>
  </other_outcome>
  <other_outcome>
    <measure>Blood markers of organ dysfunction</measure>
    <time_frame>Daily assessment in the ICU up to 12 weeks</time_frame>
    <description>Platelets, creatinine, urea, sodium, potassium, D-dimer, lactate dehydrogenase, bilirubin, lactate</description>
  </other_outcome>
  <other_outcome>
    <measure>Infiltrates on conventional chest x-ray</measure>
    <time_frame>Up to 12 weeks</time_frame>
    <description>Number of participants with unilateral infiltrates or bilateral infiltrates and/or air bronchogram</description>
  </other_outcome>
  <enrollment type="Anticipated">20</enrollment>
  <condition>COVID-19</condition>
  <condition>Respiratory Failure</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Bronchoalveolar lavage fluid Plasma Whole blood
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Mechanically ventilated COVID-19 patients with ARDS included within 3 days of ICU admission
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age &gt; 18y

          -  Mechanical ventilation

          -  Verified COVID-19 (throat swab or tracheal aspirate positive for SARS-CoV-2)

          -  ARDS according to the Berlin definition

        Exclusion Criteria:

          -  Untreated malignant tachycardia or bradycardia

          -  Suspected or verified intracranial hypertension (ICP &gt; 15 mmHg)

          -  Unilateral lung ventilation

          -  Severe non-correctable coagulopathy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ronni R Plovsing, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dept. of Intensive Care, University Hospital Hvidovre, Denmark</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ronni R Plovsing, MD, PhD</last_name>
    <phone>+45 38 62 07 21</phone>
    <email>ronni.thermann.reitz.plovsing.01@regionh.dk</email>
  </overall_contact>
  <location>
    <facility>
      <name>Dept. of Intensive Care 542, University Hospital Hvidovre</name>
      <address>
        <city>Hvidovre</city>
        <state>Copenhagen</state>
        <zip>2650</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ronni R Plovsing, MD, PhD</last_name>
      <phone>+45 38 62 07 21</phone>
      <email>ronni.thermann.reitz.plovsing.01@regionh.dk</email>
    </contact>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>April 13, 2020</study_first_submitted>
  <study_first_submitted_qc>April 19, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 21, 2020</study_first_posted>
  <last_update_submitted>April 19, 2020</last_update_submitted>
  <last_update_submitted_qc>April 19, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 21, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hvidovre University Hospital</investigator_affiliation>
    <investigator_full_name>Ronni R. Plovsing</investigator_full_name>
    <investigator_title>MD, PhD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Respiratory Insufficiency</mesh_term>
    <mesh_term>Inflammation</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

